Company

Third Harmonic Bio, Inc.

Third Harmonic Bio develops biopharmaceutical therapies for chronic urticaria and severe asthma.

About

Founded in 2019 and based in San Francisco, US, Third Harmonic Bio develops therapies for chronic urticaria and severe asthma. Its pipeline includes THB335, which targets biological pathways associated with allergic responses. The company raised USD 163.35 million in an IPO in September 2022.

2Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in